GlassScriptPhysician profile
Russell G Tacata
NPI 1356341002
$22,233.71
in general payments reported to CMS, 2019-2025
39 companies · $2,165 in 2025
The $2,165 reported for 2025 was more than what 97% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,973 · 2020: $3,925 · 2021: $3,994 · 2022: $3,625 · 2023: $2,236 · 2024: $2,316 · 2025: $2,165.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,684 · Education: $32.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,684.38 |
| Education | $32.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,610.21 | 2019-2025 | Tezspire, Farxiga, Airsupra |
| Amarin Pharma, INC. | $2,509.80 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $2,439.70 | 2021-2025 | |
| Novo Nordisk INC | $1,390.26 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,375.32 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Amgen INC. | $1,358.64 | 2019-2025 | Repatha, Krystexxa, Repatha |
| Abbvie INC. | $1,234.80 | 2019-2025 | Qulipta, Ubrelvy |
| Glaxosmithkline, LLC. | $1,010.26 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $808.50 | 2019-2025 | Jardiance, Mounjaro, Emgality |
| Horizon Therapeutics Plc | $774.85 | 2019-2023 | Krystexxa |
| Sanofi-Aventis U.S. LLC | $587.48 | 2019-2020 | |
| Pfizer INC. | $555.92 | 2019-2025 | |
| Arbor Pharmaceuticals, INC. | $527.84 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $463.00 | 2019-2025 | Zoryve, Livalo |
| Esperion Therapeutics, INC. | $370.20 | 2020-2025 | Nexletol |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Russell Tacata listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.